参考文献/References:
[1] Wang J, Zhang R. Composite lymphoma of cervical lymph nodes with classical Hodgkin lymphoma and diffuse large B cell lymphoma: a case report and literature review[J]. Ann Palliat Med, 2020, 9(5): 3651-3662.
[2] Thirumala S, Esposito M, Fuchs A. An unusual variant of composite lymphoma: a short case report and review of the literature[J]. Arch Pathol Lab Med, 2000, 124(9): 1376-1378.
[3] Esper A, Alhoulaiby S, Zuhri Y R, et al. Composite lymphoma of T-cell rich, histiocyte-rich diffuse large B-cell lymphoma and nodular lymphocyte predominant Hodgkin lymphoma: a case report[J]. J Med Case Rep, 2021, 15(1): 163.
[4] Gaurav G, Austin H Ng, Kayla K, et al. Caponetti. Composite lymphoma with diffuse large B-cell lymphoma and classical Hodgkin lymphoma components: A case report and review of the literature[J]. 2016, 212(12):1179-1190.
[5] Bellan C, Lazzi S, Zazzi M, et al. Immunoglobulin gene rearrangement analysis in composite hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells? [J]. Diagn Mol Pathol 2002, 11(1): 2-8.
[6] Rosenquist R, Menestrina F, Lestani M, et al. Indications for peripheral light-chain revision and somatic hypermutation without a functional B-cell receptor in precursors of a composite diff use large B-cell and Hodgkins lymphoma [J]. Lab Invest, 2004, 84(2): 253-262.
[7] Ramchandren R, Domingo-Domènech E, Rueda A, et al. Nivolumab for Newly Diagnosed Advanced-Stage
Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase Ⅱ CheckMate 205 Study[J]. J Clin Oncol, 2019, 37:1997-2007.
[8] Yang X, Min X, He W. Sequential development of multifocal recurrent nonHodgkins lymphoma of mucosaassociated lymphoid tissue and diffuse large Bcell lymphoma in a single patient:a case report[J]. Medicine(Baltimore), 2018, 97(21):E10845.
[9] Tomuleasa C, Iluta S, Pasca S, et al. Complete metabolic remission in an 84year old patient with relapsed/refractory diffuse large Bcell lymphoma following combination immunotherapy with lenalidomide plus rituximab[J]. Int J Hematol, 2020, 112(4):597 -598.